Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c

American Journal of Medicine

Volumn 129, Issue 3, 2016, Pages 340.e1-340.e8

  Cavender, Matthew A ^a   Scirica, Benjamin M ^a   Raz, Itamar ^b   Gabriel Steg, Ph ^c,d   McGuire, Darren K ^e   Leiter, Lawrence A ^f   Hirshberg, Boaz ^g   Davidson, Jaime ^e   Cahn, Avivit ^b   Mosenzon, Ofri ^b   Im, Kyungah ^a   Braunwald, Eugene ^a   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g ASTRAZENECA   (United Kingdom)

Author keywords

Coronary artery disease; Diabetes mellitus; Glycated hemoglobin assay; Randomized clinical trials

Indexed keywords

HEMOGLOBIN A1C; PLACEBO; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PHASE 4 CLINICAL TRIAL; RISK; STATISTICS AND NUMERICAL DATA; STROKE;

ADAMANTANE; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; INCRETINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK; STROKE;

EID: 84958053809     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.09.022     Document Type: Article

References (23)

1. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, and et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 58 2015 429 442
2. Standards of medical care in diabetes-2015: summary of revisions Diabetes Care 38 suppl 2015 S4
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 837 853
4. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577 1589
5. H.C. Gerstein, M.E. Miller, S. Genuth, and et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes N Engl J Med 364 2011 818 828
6. G.J. Blake, A.D. Pradhan, J.E. Manson, and et al. Hemoglobin A1c level and future cardiovascular events among women Arch Intern Med 164 2004 757 761
7. E. Selvin, M.W. Steffes, H. Zhu, and et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults N Engl J Med 362 2010 800 811
8. M. Schillinger, M. Exner, J. Amighi, and et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis Circulation 108 2003 2323 2328
9. J.R. Timmer, M. Hoekstra, M.W. Nijsten, and et al. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention Circulation 124 2011 704 711
10. M. Laakso Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies Ann Intern Med 124 1996 127 130
11. C.J. Currie, J.R. Peters, A. Tynan, and et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study Lancet 375 2010 481 489
12. B.M. Scirica, D.L. Bhatt, E. Braunwald, and et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study Am Heart J 162 2011 818 825.e6
13. O. Mosenzon, I. Raz, B.M. Scirica, and et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial Diabetes Metab Res Rev 29 2013 417 426
14. B.M. Scirica, D.L. Bhatt, E. Braunwald, and et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 2013 1317 1326
15. B.M. Scirica, E. Braunwald, I. Raz, and et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial Circulation 130 2014 1579 1588
16. D.L. Bhatt, and M.A. Cavender Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure? JACC Heart Fail 2 2014 583
17. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
18. H.C. Gerstein, M.E. Miller, R.P. Byington, and et al. Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
19. C. Iribarren, A.J. Karter, A.S. Go, and et al. Glycemic control and heart failure among adult patients with diabetes Circulation 103 2001 2668 2673
20. G.A. Nichols, C.M. Gullion, C.E. Koro, S.A. Ephross, and J.B. Brown The incidence of congestive heart failure in type 2 diabetes: an update Diabetes Care 27 2004 1879 1884
21. D. Aguilar, B. Bozkurt, K. Ramasubbu, and A. Deswal Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes J Am Coll Cardiol 54 2009 422 428
22. J.A. Udell, M.A. Cavender, D.L. Bhatt, S. Chatterjee, M.E. Farkouh, and B.M. Scirica Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials Lancet Diabetes Endocrinol 3 2015 356 366
23. J.J. McMurray, H.C. Gerstein, R.R. Holman, and M.A. Pfeffer Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored Lancet Diabetes Endocrinol 2 2014 843 851